OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Grows Stock Position in Arcus Biosciences, Inc. (NYSE:RCUS)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC raised its holdings in Arcus Biosciences, Inc. (NYSE:RCUS) by 140.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 76,646 shares of the company’s stock after buying an additional 44,784 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.08% of Arcus Biosciences worth $1,141,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds also recently modified their holdings of the stock. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Arcus Biosciences by 2.5% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,007 shares of the company’s stock worth $506,000 after purchasing an additional 833 shares during the period. JPMorgan Chase & Co. increased its position in Arcus Biosciences by 2.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 43,685 shares of the company’s stock worth $668,000 after purchasing an additional 1,117 shares in the last quarter. R Squared Ltd purchased a new position in Arcus Biosciences in the fourth quarter valued at approximately $26,000. Teacher Retirement System of Texas lifted its position in Arcus Biosciences by 19.2% during the fourth quarter. Teacher Retirement System of Texas now owns 14,952 shares of the company’s stock valued at $223,000 after buying an additional 2,410 shares in the last quarter. Finally, Handelsbanken Fonder AB lifted its position in Arcus Biosciences by 11.2% during the fourth quarter. Handelsbanken Fonder AB now owns 24,800 shares of the company’s stock valued at $369,000 after buying an additional 2,500 shares in the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Insider Transactions at Arcus Biosciences

In other news, CEO Terry J. Rosen purchased 19,800 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were acquired at an average cost of $10.18 per share, with a total value of $201,564.00. Following the transaction, the chief executive officer now owns 2,554,160 shares in the company, valued at approximately $26,001,348.80. The trade was a 0.78% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, Director Yasunori Kaneko acquired 20,000 shares of Arcus Biosciences stock in a transaction that occurred on Thursday, February 27th. The shares were purchased at an average price of $10.06 per share, for a total transaction of $201,200.00. Following the completion of the purchase, the director now directly owns 28,400 shares of the company’s stock, valued at $285,704. The trade was a 238.10% increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders own 12.30% of the company’s stock.

Arcus Biosciences Price Performance

Shares of NYSE RCUS opened at $8.66 on Wednesday. The company has a quick ratio of 5.24, a current ratio of 5.24 and a debt-to-equity ratio of 0.08. Arcus Biosciences, Inc. has a fifty-two week low of $6.50 and a fifty-two week high of $18.98. The business has a 50 day moving average price of $8.35 and a two-hundred day moving average price of $12.28. The firm has a market cap of $916.96 million, a PE ratio of -2.75 and a beta of 0.88.

Arcus Biosciences (NYSE:RCUS) last issued its quarterly earnings results on Tuesday, May 6th. The company reported ($1.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.02) by ($0.12). Arcus Biosciences had a negative return on equity of 45.59% and a negative net margin of 102.66%. The company had revenue of $28.00 million during the quarter, compared to the consensus estimate of $38.61 million. During the same quarter last year, the firm posted ($0.05) EPS. The firm’s quarterly revenue was down 80.7% on a year-over-year basis. Sell-side analysts expect that Arcus Biosciences, Inc. will post -3.15 earnings per share for the current fiscal year.

Analysts Set New Price Targets

RCUS has been the subject of several recent research reports. The Goldman Sachs Group lowered their price target on Arcus Biosciences from $15.00 to $13.00 and set a “neutral” rating for the company in a report on Thursday, May 8th. Morgan Stanley lowered their target price on Arcus Biosciences from $24.00 to $22.00 and set an “overweight” rating for the company in a research note on Friday, May 9th. Wedbush reissued an “outperform” rating and set a $33.00 price target on shares of Arcus Biosciences in a research report on Wednesday, May 7th. Barclays decreased their price target on Arcus Biosciences from $29.00 to $14.00 and set an “overweight” rating for the company in a report on Wednesday, April 23rd. Finally, HC Wainwright raised shares of Arcus Biosciences from a “neutral” rating to a “buy” rating and increased their price objective for the company from $18.00 to $24.00 in a research report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $25.67.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.